STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #120 by analyst upside · 2026-06-27
CTSO
Cytosorbents Corporation
Healthcare · Market Cap $23M · P/E 0x
ANALYST PRICE TARGET
+694.2%
implied upside to consensus target
Current Price $0.36
Consensus Target $2.88
Bull Target $5.0
Bear Target $0.75
Analysts Covering 2
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
1
Hold
1
Sell
0
52-Week Low $0.36
52-Week High $1.3
YTD Return -44.8%
FUNDAMENTALS
Market Cap $23M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.19
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $37M
Profit Margin -31.8%
52-WEEK RANGE
52-Week Low $0.36
52-Week High $1.3
Current Price $0.36
Bear Target $0.75
Bull Target $5.0
● Now $0.36 ● Target $2.88
TRADING DATA
Avg Volume 158K
YTD Return -44.8%
Analyst Count 2
Consensus Buy
Upside to Target +694.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Cytosorbents Corporation (CTSO) is currently trading at $0.36 with a Wall Street consensus price target of $2.88, implying potential upside of 694.2% over the next 12 months. 2 analysts currently cover CTSO, with a consensus rating of Buy — 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $5.0, while the most cautious has a target of $0.75.

CTSO operates in the Healthcare sector with a market capitalisation of $23M. The stock is down 44.8% year-to-date and is currently trading near the lower end of its 52-week range of $0.36 – $1.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →